Siavash Kijani

Siavash Kijani is a specialist at Novo Nordisk since November 2024, with previous experience as a senior scientist at AstraZeneca from September 2020 to October 2024, and as a scientist at Affibody AB from August 2018 to August 2020, where responsibilities included generating biological leads through phage display and designing validation assays. Earlier roles include a researcher PhD candidate at Sahlgrenska Academy at Gothenburg University, focusing on atherosclerosis from March 2011 to January 2017, and as a laboratory technician at AstraZeneca, where work involved protein expression and purification from May 2009 to September 2010. Siavash Kijani's initial role was in sales at GodEl i Sverige AB in 2007. Educational qualifications include a PhD in Medical Science with a focus on Cardiovascular Research from the University of Gothenburg (2011-2017) and a Master of Science in Medicinal and Pharmaceutical Chemistry from the same institution (2004-2010).